Momenta Phama (MNTA) Tops Q2 EPS by 20c

Momenta Phama (NASDAQ: MNTA) reported Q2 EPS of ($0.46), $0.20 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $23.4 million versus the consensus estimate of $24.49 million.

• Company reports Glatopa® 20 mg product revenues of $23 million, a 58% increase over the same period in 2016
• Ended the first quarter with a strong cash position of $434 million

For earnings history and earnings-related data on Momenta Phama (MNTA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c